In order to confirm that inhibition of MAPK pathway would be more effective in inhibiting the growth of GIST cell lines, we used another MEK inhibitor trametinib (TR) (a FDA approved drug), either alone or in combination with KIT inhibitors and GD. This evidence concerns the gene MAP2K7 and gastrointestinal stromal tumor.